Madrigal Pharmaceuticals (NASDAQ:MDGL) stock declined 4% in pre-market trading Monday after the FDA approved Novo Nordisk’s (NYSE:NVO) Wegovy for treating adults with noncirrhotic metabolic ...

Price hikes are 'kick in the teeth' for patients who will either have to swallow 170 per cent price increase, or switch to ...

US futures already pricing in an 85% chance of a September cut, with much of the ‘good news’ likely baked in, said traders. Of the S&P 500 companies that have already declared results, nearly 82% have ...

U.S. stock futures are ticking lower after indexes finished higher for a second straight week. Investors are looking ahead this week to key remarks from Fed Chair Jerome Powell and a string of ...

U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with ...

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

Dow Jones Top Company Headlines at 7 AM ET: FDA Approves Novo Nordisk's Wegovy for Liver Disease | How ... Novo Nordisk shares climbed after the U.S. Food and Drug Administration approved a new ...

But now, women have complained of 'Ozempic vulva' and its side effects. One woman on Reddit complained of 'pain when biking ...

Novo Nordisk stock rose after good news from the FDA on Wegovy—it’s popular weight-loss drug which has the same active ...

Novo Nordisk's shares saw an uptick following the FDA's approval of Wegovy, its flagship drug, to treat a severe fatty liver disease.

On Saturday, the U.S. Food and Drug Administration (FDA) approved an additional indication for Novo Nordisk A/S’ (NYSE:NVO) ...